Healthy Individuals
Conditions
Brief summary
The hippocampus is particularly laden with n-methyl-d-aspartate (NMDA) receptors, and is at the same time one of the most important sites in declarative memory. The rationale of this study is that the NMDA partial agonist D-Cycloserine will promote learning compared to a placebo. On the other hand, the NMDA receptor antagonist Memantine might lead to reduced memory. We believe that the influence of NMDA receptors on memory can be determined via acute co-activation of the NMDA receptors with Cycloserine® (King Pharmaceuticals Ltd, active ingredient: DCycloserin, dose: 250 mg) and Memantine (Axura®, Merz, active ingredient: Memantine, dose: 20 mg)on both a behavioral and functional (fMRI) level.
Interventions
DRUGSugar pill
250 mg, one dose, 60 min prior
DRUGGlutamic Acid
250 mg, one dose, 60 minutes prior
DRUGMemantine
20 mg, one dose, 8 hours prior
Sponsors
University Hospital, Bonn
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* German native language or native language level * Able to give written informed consent * right-handed
Exclusion criteria
* inability to give written informed consent, underaged minors, contractually incapable persons, persons in legal custody * any psychiatric, neurological or internal illness * hematoporphyria (enzyme sickness) * intake of medication (except oral contraceptives) * simultaneous participation in other clinical studies * hypersensitivity to Memantine or other anti-dementia substances, or to D-Cycloserine * alcohol abuse * epilepsy * depression * serious anxiety or psychosis * serious kidney insufficiency * intake of Ethionamide or Isoniazide * pregnancy or women who are nursing * liver or kidney problems * intake of NMDA-antagonists, such as Amantadine, Ketamine, or Dextromethorphan * vegetarians * stomach ulcer, if treated with medication * renal tubular acidosis * urinary infections (with proteus bacteria) * recent heart attack, heart failure, or uncontrolled high blood pressure * intake of L-Dopa, dopaminergic agonists, and anticholinergics * intake of barbiturates, spasmolytics, Phenytoin, Amantadine, oral coagulators, warfarin, HCT (Hydrochlorothiazide) * heart or cranial operations * pacemaker, medication pump (such as insulin pump), hearing aid, removable prosthodontics * metal in or on body (such as acupuncture needles, artificial limbs, stents, metal splints, clips, implanted electrodes, tattoos, or piercings) * claustrophobia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| fMRI during learning task | once at drug administration |
Countries
Germany
Outcome results
None listed